<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02248519</url>
  </required_header>
  <id_info>
    <org_study_id>NL47444.041.14</org_study_id>
    <nct_id>NCT02248519</nct_id>
  </id_info>
  <brief_title>Laparoscopic Versus Open Gastrectomy for Gastric Cancer</brief_title>
  <acronym>LOGICA</acronym>
  <official_title>Laparoscopic Versus Open Gastrectomy for Gastric Cancer, a Multicenter Prospectively Randomized Controlled Trial (LOGICA-trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first randomized controlled trial comparing laparoscopic and open gastrectomy for
      resectable gastric cancer in a Western population. The hypothesis is that laparoscopic
      gastrectomy will result in a lower post-operative burden by means of shorter post-operative
      hospital stay. Secondarily that laparoscopic gastrectomy is hypothesized to be associated
      with lower post-operative morbidity and readmissions, higher cost-effectiveness, and better
      post-operative quality of life, with similar mortality and oncologic outcomes, compared to
      open gastrectomy. The study starts on 1 December 2014. Inclusion and follow-up will take
      three and five years respectively. Short-term results will be analyzed and published after
      discharge of the last randomized patient.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative hospital stay</measure>
    <time_frame>During admission, an expected average of 2 weeks</time_frame>
    <description>The primary outcome of this study is the post-operative hospital stay (days), since this is considered a strong end point as it reflects the impact of the different surgical procedures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days post-operative</time_frame>
    <description>Measured as 30-day mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative morbidity</measure>
    <time_frame>Up to 5 years post-operative</time_frame>
    <description>Complications will be classified according to the Clavien-Dindo system and include anastomotic leakage, anastomotic stricture, respiratory complications, cardiac complications, intra-abdominal bleeding , intra-abdominal abscess, sepsis, ileus, wound infection, fistula, urinary tract infection and dumping syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>Up to 5 years post-operative</time_frame>
    <description>Cost-effectiveness will be calculated by comparing the direct medical cost related to both strategies up until five years after the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Up to 5 years post-operative</time_frame>
    <description>The validated quality of life questionnaires Short Form-36 (SF-36), EORTC QLQ-30 and EORTC QLQ-STO22 will be filled in pre-operative &lt;5 days and post-operative at 6 weeks, 12, 24, 36, 48 and 50 months after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmissions</measure>
    <time_frame>Up to 5 years post-operative</time_frame>
    <description>The number of post-operative readmissions</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Perioperative blood loss</measure>
    <time_frame>Post-operative day 1</time_frame>
    <description>Measured in milliliters (ml)</description>
  </other_outcome>
  <other_outcome>
    <measure>Operative time</measure>
    <time_frame>Post-operative day 1</time_frame>
    <description>The time from incision to closure of all wounds in minutes (min)</description>
  </other_outcome>
  <other_outcome>
    <measure>Conversion rate</measure>
    <time_frame>Post-operative day 1</time_frame>
    <description>The percentage (%) of laparoscopic gastrectomies that had to be converted intra-operatively to an open procedure due to any reason.</description>
  </other_outcome>
  <other_outcome>
    <measure>Survival</measure>
    <time_frame>Up to 5 years post-operative</time_frame>
    <description>Measured as 5-year disease free survival and 5-year overall survival</description>
  </other_outcome>
  <other_outcome>
    <measure>VAS-score</measure>
    <time_frame>Post-operative day 1 and 2</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Surgeons ergonomics</measure>
    <time_frame>Post-operative day 1</time_frame>
    <description>Measured with the Subjective Mental Effort Questionnaire (SMEQ)</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to return to normal nutritional regime</measure>
    <time_frame>Up to 5 years post-operative</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to return to daily activity</measure>
    <time_frame>Up to 5 years post-operative</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Open Gastrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic Gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open Gastrectomy</intervention_name>
    <description>Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group</description>
    <arm_group_label>Open Gastrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic Gastrectomy</intervention_name>
    <description>Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy. If laparoscopic resection does not seem feasible during surgery, the procedure may be converted to an open gastrectomy.</description>
    <arm_group_label>Laparoscopic Gastrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven adenocarcinoma of the stomach

          -  Surgically resectable (cT1-4a, N0-3b, M0) tumor

          -  Age â‰¥ 18 years

          -  European Clinical Oncology Group (ECOG) performance status 0, 1 or 2.

          -  Written informed consent

        Exclusion Criteria:

          -  Siewert type I esophagogastric junction tumor

          -  Non-elective surgery

          -  Previous gastric resection or recurrent gastric cancer

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard van Hillegersberg, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Surgery, University Medical Center Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zorggroep Twente Almelo</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medical Center</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Hospital</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orbis Medical Center</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Haverkamp L, Brenkman HJ, Seesing MF, Gisbertz SS, van Berge Henegouwen MI, Luyer MD, Nieuwenhuijzen GA, Wijnhoven BP, van Lanschot JJ, de Steur WO, Hartgrink HH, Stoot JH, HulsewÃ© KW, Spillenaar Bilgen EJ, RÃ¼tter JE, Kouwenhoven EA, van Det MJ, van der Peet DL, Daams F, Draaisma WA, Broeders IA, van Stel HF, Lacle MM, Ruurda JP, van Hillegersberg R; LOGICA study group. Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial). BMC Cancer. 2015 Jul 29;15:556. doi: 10.1186/s12885-015-1551-z.</citation>
    <PMID>26219670</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>September 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Richard van Hillegersberg</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>Gastrectomy</keyword>
  <keyword>Laparoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

